Stemline Therapeutics, Inc. is a rising star in the biopharmaceutical industry engaged in developing innovative cancer therapeutics. With three promising product candidates in its pipeline, the company is already in the clinical stage of development. One of its leading products, SL-401, is currently undergoing potentially pivotal Phase 2 trials to evaluate its efficacy in treating hematologic cancers by targeting the interleukin-3 receptor present in affected cells. Stemline's focus on developing treatments for oncology and neurology is expected to position it as a significant player in the biopharmaceutical industry in the years to come.
Stemline Therapeutics's ticker is STML
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 11-50 employees working at Stemline Therapeutics
It is http://www.stemline.com
Stemline Therapeutics is in the Healthcare sector
Stemline Therapeutics is in the Biotechnology industry
The following five companies are Stemline Therapeutics's industry peers: